Loading clinical trials...

COMPLETEDNA

Kidney Fibrosis and MRI

Development of Novel MRI Methods for Detecting and Measuring Renal Injury/Fibrosis

NCT03964948•Children's Hospital Medical Center, Cincinnati

Summary

The investigators plan a prospective cross-sectional study of pediatric and adult healthy volunteers and patients with chronic kidney disease that will correlate a variety of quantitative MRI biomarkers with severity of renal insufficiency and available histopathology. Over 3 years, the investigators will recruit approximately 20 healthy volunteers, 20 patients with chronic kidney disease (CKD) Stage 2-5, and 20 patients with renal transplant kidneys. The investigators also plan to assess the effect of inflammation on the quantitative MRI biomarkers by recruiting approximately 20 additional patients with active lupus nephritis.

Eligibility

Age

10 - 25 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Subjects who meet all of the following criteria will be eligible for the study:
•1. ≥ 10 and ≤ 25 years of age and;
•2. Kidney transplant patients, who have had a recent kidney biopsy (within 1 year) that shows interstitial fibrosis OR
•3. Patients with CKD Stage 2-5 who have previously had a biopsy (within 1 year) OR
•4. Lupus patients with active nephritis who will undergo biopsy evaluation before and after induction therapy OR
•5. Healthy Controls

Exclusion Criteria

•Subjects who meet any of the following criteria will be excluded from the study:
•1. Known contraindication to MR imaging (e.g., implanted non-MRI compatible device)
•2. Known or suspected pregnancy. Female subjects of child bearing potential will undergo a urine pregnancy test prior to imaging.
•3. Inability to undergo MRI without sedation/anesthesia.
•4. Non-English Speaking

Locations (1)

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States

Key Dates

Start Date

August 6, 2018

Primary Completion Date

June 18, 2021

Completion Date

June 18, 2021

Last Updated

September 9, 2021

Enrollment

ACTUAL participants

Conditions

Kidney Diseases

Interventions

Kidney MRI

DIAGNOSTIC_TEST

A Contrast Medium Sparing Strategy Using Automated CO2 Injection During PVI for Prevention of Major Adverse Kidney Events (MAKE)

NCT06656988

Peripheral Vascular DiseasesKidney Diseases

View study

RECRUITINGEARLY_PHASE1

Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis

NCT04592640

Chronic Kidney DiseasesCalciphylaxis+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 9, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Kidney Fibrosis and MRI

Inclusion Criteria

Exclusion Criteria

A Contrast Medium Sparing Strategy Using Automated CO2 Injection During PVI for Prevention of Major Adverse Kidney Events (MAKE)

Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis

Handgrip Exercise Training and CKD

Eye-Brain-Kidney in CKD

Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Chronic Kidney Disease (CKD)